Pathstance - Transforming a simple, prescribed NHS wearable, into a sensor-rich, at-home monitoring and rehabilitation device

Joint surgery (arthroplasty) costs the NHS more than £1.4bn/annum, with 321,000 conducted per annum wit volume growing.

These operations are not only expensive (~£11,433 Knee/~£33,321 Hip; a 39% increase in real cost since 2012), they also require extensive, patient-led, at-home prehabilitation and rehabilitation exercises if they are to be truly successful and for patients to regain their full mobility and quality-of-life.

Unfortunately, however, more than 50% of all arthroplasty patients do not continue recommended rehabilitation exercises or aftercare, leading to worsened pain, reduced functional state, and significant social care cost to the UK economy.

Addressing a key NHS demand for accurate and reliable at-home rehabilitation devices, PathStance (Ps), is a game-changing at-home telemedicine system that combines unique and patented sensor-rich insoles and patient-adapting machine learning to accurately map, metricate, and baseline a person's gait symmetry, pressure distribution, balance, and fall-risk, among a range of other clinically accurate metrics, in real-time. This data is then used in combination with haptics and physiotherapy to provide highly-accurate corrective feedback to users in real-time for at-home rehabilitation exercises and provides clinicians with accurate, quantifiable data from which improvements to care plans can be made.

In early trials, this approach has proven successful in increasing activity levels in aging populations, reducing foot ulcer risk, and improving adherence and engagement with prescribed care rehabilitation plans.

For the NHS, our technology will improve access to rehabilitation services; provide clinically accurate data to clinicians; support NHS, NICE, and UK GOV policies on healthy ageing, telemedicine, and recovery empowerment; enable arthroplasty patients to recover health, movement, and quality of life up to 30% faster than current care approaches alone.

Ultimately, we believe the technology will help the NHS save ~£1,418 in non-operative treatment costs per patient = £248m potential saving per annum, equivalent to~18% of total NHS arthroplasty spend.